Immunome (IMNM) said late Wednesday it priced an underwritten public offering of about 19.4 million shares at $7.75 per share for expected gross proceeds of $150 million.
Immunome said it has granted the underwriters a 30-day option to purchase up to an additional 2.9 million shares.
The offering is expected to close on Friday.